Amgen picks up an edge for Repatha in duel with Sanofi and Regeneron

re

Amgen has a new tool to employ in its battle with Sanofi and Regeneron for PCSK9 market dominance. The drugmaker said today that the FDA has approved a new hands-free injector for a once-monthly dose of the drug that it expects to have on the market within weeks.

Amgen ($AMGN) said the FDA approved its Pushtronex, an on-body infusor with a prefilled cartridge, to give a single monthly dose. The device will carry the WAC price of $14,100 annually, the same as the twice-weekly product, the Thousand Oaks, CA-based company said in its announcement.

When Repatha was first approved by the FDA in August 2015, the dosing was 140 mg every two weeks or 420 mg once monthly. Until the approval of the single-dosing option, the 420-mg monthly dose required three 140-mg injections to be administered consecutively within 30 minutes. 

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

“Repatha is the only PCSK9 inhibitor with an approved monthly dose, and now the only one with a monthly single-dose administration," the company said in its announcement.

Amgen’s Repatha and Sanofi ($SNY) and Regeneron's ($REGN) Praluent are scrapping for every bit of leverage for their new drugs, which block a protein that inhibits the body's natural system to eliminate "bad" cholesterol. When they were near approval last year, analysts had very high expectations, believing they would be used along with the inexpensive generic statins that millions of people currently take for lowering cholesterol, or at least for those who can’t tolerate statins.

But the FDA stopped short of designating them for that indication. Instead, they're approved for patients with a hereditary form of high cholesterol, and those at high risk of heart problems who haven't responded to aggressive statin therapy.

That gave payers the defense they needed to limit use of the drugs, whose annual cost is way beyond that of cheap generic statins. Instead of allowing doctors carte blanche authority to prescribe them, payers are requiring them and their patients to go through a document-intensive preapproval process.

Those difficulties have kept sales low so far.  Analysts have forecast that both drugs could generate about $3 billion in annual sales by 2022. Repatha was forecast to have about $185 million in sales this year and Praluent as much as $265 million, yet in the first quarter both turned in only about $20 million.

- here’s the announcement

Related Articles:
NICE gives tentative broad approval to both Repatha, Praluent
Express Scripts: Pricey PCSK9 drugs poised to 'wreak havoc'
Two's company for PCSK9 meds as Praluent, Repatha both nab coverage from top PBM

Read more on

Suggested Articles

Several Johnson & Johnson drugs are contributing strong growth, but some struggling medicines weighed on the company's overall performance.

J&J has received its fair share of barbs Oklahoma's bench trial. Whether it'll be held responsible for the state's opioid crisis is now up…

J&J's pharma unit is still on the upswing, thanks to newer meds like Stelara, but execs had to explain disappointing numbers from two blockbusters.